Track the KLABIN S.A. share price and the full directors' dealings record of the company, a listed equity based in Brazil. Shares trade on BR BR, under the authority of CVM (Brazil). Operating in the Chemicals sector, KLABIN S.A. has published 1,433 reports. Market capitalisation: €21.3bn. The latest transaction was filed on 8 June 2026 (Compra à vista (Crédito)). Among the most active insiders: Anonymous (Conselho de Administração ou Vinculado). All data is free.
KLABIN S.A. reported a total of 430 insider trading declarations over the last 90 days. There were no purchases or sales recorded in euros. The top insiders included individuals in the roles of Conselho de Administração ou Vinculado and Diretor ou Vinculado. The highest total amount reported by an insider was approximately 3.8 million euros from an anonymous member of the Conselho de Administração ou Vinculado, with 193 declarations. Another anonymous insider in the Diretor ou Vinculado role reported around 1.4 million euros across 68 declarations. Notable recent declarations include multiple purchases by an anonymous insider from the Conselho de Administração on June 8, 2026, with amounts ranging from approximately 171,000 to 968,000 euros. Additionally, there were sales recorded by an anonymous insider in the Diretor ou Vinculado role on the same date, totaling around 172,000 euros.
Auto-generated summary, refreshed daily.Updated 3d ago
1,433
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
14Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 6,105 of 26,179 companies
64.9
score / 100
Value
84
Quality
46
FCF yld17%
Earn yld6.6%
EV/EBITDA5.7x
ROE5.5%
Gross mgn35%
Net mgn6.8%
Debt/EBITDA3.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.